With the preparation and application of Leuprorelin-containing medicinal products being complicated and error-prone, the Pharmacovigilance Risk Assessment Committee (PRAC) within the European Medicines Agency recommends new measures to avoid application errors. The Committee especially advises that exclusively medical professionals who are familiar with the preparation of Leuprorelin-containing depot medicinal products should be allowed to prepare and inject them. Patients should not do this themselves. For more information please click here.
May
19
Comments are closed.